“Working with regulators, we look forward to establishing tools to create a stronger foundation of analytical methods for psychedelic compounds and products.”

Vancouver-based Numinus Wellness has announced the development of proprietary methods for testing and screening psychedelic mushroom compounds.

The company, which can legally possess, produce and export a number of psychedelics, including ketamine and Lysergic acid diethylamide (LSD), is developing testing methods for the active constituents, contaminants and residues in mushroom fruiting bodies, extracts and derivatives.“The testing we’ve developed and validated at Numinus Bioscience will facilitate the safety and efficacy testing of psychedelics for our products, our clients and strategic partners, and, ultimately, the industry,” says Sharan Sidhu , the company’s science officer and general manager.

Earlier this year, Numinus partnered with Optimi Health, a mushroom brand focused on the health and wellness markets, on an information package that was sent to Health Canada. The package included the chemical constituents of an investigational product, genotype and formulation information, and procedures and processes to produce a consistent dosage from psilocybe mushrooms.

The company completed its first legal harvest of psilocybe mushrooms last October.

“Now, we can progress with research and development of standardized cultivation, extraction and testing methods, and exploring product formulations to support safe, evidence-based, accessible psychedelic-assisted psychotherapy, as well as build a sequenced spore library,” Michael Tan, the company’s chief operating officer, said at the time.